News & Perspective

May 10, 2013

May 10, 2013

Experts offer dim view of potential vaccine response to H7N9

If the H7N9 influenza virus now circulating in China evolves into a pandemic strain, the world is likely to have great difficulty providing adequate supplies of an effective vaccine in time to blunt its impact, according to a viewpoint article by three experts in the Journal of the American Medical Association (JAMA).

Dec 11, 2012

Dec 11, 2012

HHS offers some forecasts on medical countermeasures

(CIDRAP News) – A new report from the US Department of Health and Human Services (HHS) offers a few predictions on when certain new countermeasures against biological threats will become available, including a forecast for two novel influenza drugs and possibly a next-generation anthrax vaccine within the next 5 years.

Nov 21, 2012

Nov 21, 2012

FDA clears first cell-based flu vaccine

(CIDRAP News) – The US Food and Drug Administration (FDA) yesterday approved the nation's first cell-based flu vaccine, a product from Novartis that uses technology that could help vaccinate more Americans in a pandemic but still has many of the same limitations of older egg-based flu vaccines.

Oct 15, 2012

Oct 15, 2012

Report: Complacency, misperception stymie quest for better flu vaccines

The world needs much better influenza vaccines, but the quest for them faces a formidable barrier: overconfidence about the effectiveness of existing influenza vaccines.

Nov 20, 2008

Nov 20, 2008

Report says pandemic will threaten coal, power supplies

(CIDRAP News) – A new report from the University of Minnesota warns that an influenza pandemic could disrupt the coal industry, thereby endangering the nation's significantly coal-dependent electric power system and everything that depends on it.

Jul 23, 2008

Jul 23, 2008

New pandemic vaccine plan keeps focus on critical workers

(CIDRAP News) – Federal health officials today released their official guidance on allocating vaccine during an influenza pandemic, with few changes from a previous draft that put military personnel, critical health and emergency workers, pregnant women, and small children at the head of the line.

Nov 15, 2007

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE Can we vaccinate enough people in time to matter?

Maryn McKennaContributing Writer

(CIDRAP News) – This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Jan 17, 2007

Jan 17, 2007

HHS funds work on dose-sparing H5N1 vaccines

(CIDRAP News) – In an effort to stretch the nation's supply of vaccines for a potential influenza pandemic, federal health officials today announced contracts totaling $132.5 million to help three companies develop dose-sparing substances, or adjuvants, to be used with H5N1 flu vaccines.

Dec 29, 2006

Dec 29, 2006

Feds detail progress on pandemic preparedness

(CIDRAP News) – In a recent update on pandemic influenza preparedness planning, the US government reported meeting more than 90% of a long list of objectives it set for itself about 6 months ago.

The report charts progress on a wide range of preparedness measures, from shoring up laboratory capabilities to planning for distribution of critical medical supplies and preparing checklists for various sectors of the economy.

Apr 11, 2006

Apr 11, 2006

Would an imperfect vaccine be useful in a flu pandemic?

(CIDRAP News) – A mathematical modeling study suggests that a modestly effective vaccine could keep an influenza pandemic from striking more than 10% of the US population, but only if large amounts of vaccine were distributed quickly and the virus was not too highly contagious.

Pages

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»